

CITATION REPORT

List of articles citing

The effect of ruboxistaurin on nephropathy in type 2 diabetes

DOI: 10.2337/diacare.28.11.2686
Diabetes Care, 2005, 28, 2686-90.

Source: <https://exaly.com/paper-pdf/38780065/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
271	Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?. <i>Diabetes Care</i> , 2005 , 28, 2803-5	14.6	9
270	Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. 2006 , 5, 835-45		37
269	PKC-B inhibition: a new therapeutic approach for diabetic complications?. 2006 , 32, 205-13		33
268	Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. 2006 , 23, 1007-45		305
267	New potential agents in treating diabetic kidney disease: the fourth act. 2006 , 66, 2287-98		21
266	Microvascular complications of diabetes. 2006 , 41, 719-36, ix		4
265	Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. 2006 , 113, 2221-30		218
264	Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. 2006 , 6, 908-17		79
263	Ruboxistaurin: a promising new treatment for use in diabetic nephropathy. 2006 , 2, 60-60		
262	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. 2006 , 2006, 28-30		
261	Current World Literature. 2006 , 15, 537-559		
260	Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. 2006 , 70, 1223-33		163
259	Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors. 2006 , 14, 5781-94		34
258	Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. 2006 , 45, 13970-81		86
257	Current literature in diabetes. 2006 , 22, i-xii		
256	Disposition of [¹⁴ C]ruboxistaurin in humans. 2006 , 34, 1909-17		8
255	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. 2006 , 1, 193-208		44

254	Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy. 2006 , 3, 172-8		38
253	Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. 2006 , 55, 3112-20		151
252	Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta β actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. 2007 , 56, 1410-20		46
251	The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy. 2007 , 56, 2371-9		34
250	Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. 2007 , 293, F565-74		27
249	The podocyte: a potential therapeutic target in diabetic nephropathy?. <i>Current Pharmaceutical Design</i> , 2007 , 13, 2713-20	3.3	39
248	A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. <i>Diabetes Care</i> , 2007 , 30, 896-902	14.6	99
247	Nailing down PKC isoform specificity in diabetic nephropathy two β company, three β a crowd. 2007 , 22, 2421-5		25
246	Diabetes and the endothelium. 2007 , 62, 97-101		27
245	Diabetic nephropathy: where hemodynamics meets metabolism. 2007 , 115, 69-84		126
244	Geriatric Diabetes. 2007 ,		2
243	Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. 2007 , 56, 346-54		77
242	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <i>Endocrine Practice</i> , 2007 , 13 Suppl 1, 1-68	3.2	446
241	Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. 2007 , 2, 631-6		67
240	Protein kinase C-beta inhibition: a promise not yet fulfilled. 2007 , 2, 619-20		5
239	Diabetic retinopathy and diabetic neuropathy. <i>Diabetes Care</i> , 2007 , 30, 760-5	14.6	14
238	Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 995-6	14.6	42
237	Treating insulin resistance: future prospects. 2007 , 4, 20-31		30

- 236 Current world literature. *Clinical nephrology*. **2007**, 16, 143-58
- 235 Bibliography. Current world literature. *Diabetes and the endocrine pancreas*. **2007**, 14, 170-96
- 234 Bibliography. Current world literature. *Molecular genetics*. **2007**, 22, 225-45
- 233 Anti-vascular endothelial growth factor therapy for ocular neovascular disease. **2007**, 18, 502-8 191
- 232 Protein kinase C beta inhibition: the promise for treatment of diabetic nephropathy. **2007**, 16, 397-402 17
- 231 The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. **2007**, 170, 1267-76 79
- 230 The management of CKD: a look into the future. **2007**, 72, 1316-23 39
- 229 Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. **2007**, 27, 153-60 71
- 228 The role of protein kinase C activation and the vascular complications of diabetes. **2007**, 55, 498-510 330
- 227 PKC inhibition and diabetic microvascular complications. **2007**, 21, 573-86 54
- 226 The role of protein kinase C activation in diabetic nephropathy. **2007**, S49-53 122
- 225 Role of protein kinase C inhibition in the development of diabetic microvascular complications. **2007**, 2, 321-329
- 224 Protein kinase C inhibition in diabetic retinopathy and microvascular disease. **2007**, 24, 263-268 1
- 223 Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. **2007**, 6, 617-35 119
- 222 Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin. **2007**, 82, 181-6
- 221 Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention. *Diabetes, Obesity and Metabolism*, **2007**, 9, 792-8 6.7 7
- 220 Diabetic nephropathy without the diabetes: if not hyperglycaemia, then what?. **2007**, 12, 67-8
- 219 Microvascular permeability in diabetes and insulin resistance. **2007**, 14, 363-73 59

218	GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-beta1 and plasma glucose concentration. 2007 , 50, 2209-17		28
217	The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. 2008 , 51, 1347-55		98
216	Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. 2008 , 22, 231-40		32
215	PKCdelta regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K. 2008 , 20, 969-77		30
214	Glycemic control in diabetic CKD patients: where do we stand?. 2008 , 52, 766-77		62
213	Diabetic neuropathy: mechanisms to management. 2008 , 120, 1-34		483
212	Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin. <i>Journal of Diabetes and Its Complications</i> , 2008 , 22, 88-95	3.2	27
211	The role of inflammatory cytokines in diabetes and its complications. 2008 , 79, 1527-34		401
210	Tratamiento de la nefropatía diabética. 2008 , 55, 105-108		
209	Protein kinase C-beta inhibition for diabetic kidney disease. 2008 , 82 Suppl 1, S70-4		30
208	Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. 2008 , 172, 628-37		109
207	Investigational drugs for diabetic nephropathy. 2008 , 17, 1487-500		9
206	Inhibition of protein kinase Cbeta prevents foam cell formation by reducing scavenger receptor A expression in human macrophages. 2008 , 118, 2174-82		39
205	Diabetes. 2008 ,		1
204	Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C beta1 in the diabetic fat tissue. 2008 , 294, E1169-77		23
203	Role of inflammation in diabetic nephropathy. 2008 , 4, 10-7		126
202	New therapeutic agents for diabetic kidney disease. 2008 , 5, 553-575		4
201	Agents in development for the treatment of diabetic nephropathy. 2008 , 13, 447-63		14

200	Diabetic patients and kidney protection: an attainable target. 2008 , 26, S3-7	5
199	Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. 2008 , 17, 143-8	29
198	Update on the treatment of diabetic retinopathy. 2008 , 8, 98-120	28
197	Evaluation of renal gene expression of protein kinase C (PKC) isoforms in diabetic and nondiabetic proliferative glomerular diseases. 2008 , 8, 835-44	6
196	Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthase-mediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. 2009 , 58, 2355-64	40
195	Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. 2009 , 24, 1782-90	18
194	Emerging therapies for chronic kidney disease: what is their role?. 2009 , 5, 375-83	59
193	Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells. 2009 , 150, 63-74	44
192	Inhibition of protein kinase C in diabetic nephropathy--where do we stand?. 2009 , 24, 2021-3	17
191	Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. 2009 , 2, 129-37	92
190	Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. 2009 , 25, 57-63	28
189	Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. 2009 , 23, 17-24	48
188	Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. 2009 , 52, 765-75	36
187	Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. 2009 , 70, 401-7	31
186	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. 2009 , 8, 417-29	245
185	(-)-Cercosporamide derivatives as novel antihyperglycemic agents. 2009 , 19, 724-6	5
184	Protein kinase C: from its specific molecular structure to its role in diabetic neuropathy. 2009 , 3, 14-22	1
183	Ruboxistaurin: PKC-beta inhibition for complications of diabetes. 2009 , 10, 2913-25	46

182	Novel therapies of diabetic nephropathy. 2009 , 18, 107-11	23
181	Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. 2010 , 304, 881-9	49
180	Role of protein kinase C in diabetic complications. 2010 , 5, 77-88	3
179	Potential new therapeutic agents for diabetic kidney disease. 2010 , 55, 928-40	76
178	Ruboxistaurin: Review of Safety and Efficacy in the Treatment of Diabetic Retinopathy. 2010 , 2, CMT.S5046	8
177	Diabetic Kidney Disease: Current Challenges. 2010 , 39-56	2
176	Complications and Management of Chronic Kidney Disease. 2010 , 145-163	1
175	Activation of protein kinase C isoforms and its impact on diabetic complications. 2010 , 106, 1319-31	600
174	Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. 2010 , 298, F1306-12	35
173	Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetes. 2010 , 95, 3783-7	20
172	Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. 2010 , 28, 497-516	6
171	The renal effects of blood glucose-lowering plant-derived extracts in diabetes mellitus--an overview. 2010 , 32, 132-8	12
170	New pharmacological treatments for improving renal outcomes in diabetes. 2010 , 6, 371-80	92
169	New approaches to the treatment of nephropathy in diabetes. 2011 , 20, 1057-71	13
168	Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. 2011 , 18, 300-11	11
167	Pathophysiology of the diabetic kidney. 2011 , 1, 1175-232	121
166	Regulation of Endothelial Barrier Function. 2011 , 3, 1-146	21
165	Oral protein kinase c inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C Inhibitor-Diabetic Retinopathy Study 2. 2011 , 31, 2084-94	82

164	Protein kinase C η inhibition ameliorates experimental mesangial proliferative glomerulonephritis. 2011 , 16, 649-55	1
163	Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats. 2011 , 162, 163-74	24
162	Novel Drug Treatment for Diabetic Nephropathy. 2011 , 13, 19-26	0
161	2D and 3D QSAR analyses to predict favorable substitution sites in anilino-monoindolylmaleimides acting as PKC η selective inhibitors. 2011 , 20, 1188-1199	2
160	Antioxidants in the treatment of diabetes. 2011 , 7, 106-25	126
159	Regenerative therapies for diabetic microangiopathy. 2012 , 2012, 916560	23
158	Differential activations of PKC/PKA related to microvasculopathy in diabetic GK rats. 2012 , 302, E173-82	9
157	Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. 2012 , 25, 514-23	68
156	Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?. 2012 , 64, 880-900	55
155	Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. 2012 , 23, 123-30	116
154	Inhibition of protein kinase C δ ameliorates impaired angiogenesis in type I diabetic mice complicating myocardial infarction. 2012 , 76, 943-9	15
153	Protein kinase C, an elusive therapeutic target?. 2012 , 11, 937-57	390
152	Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients. 2012 , 44, 1771-7	10
151	JDRF perspective: bridging the gap-translational research to prevent progression of diabetic nephropathy. 2012 , 32, 512-6	
150	Implications of treatment that target protective mechanisms against diabetic nephropathy. 2012 , 32, 471-8	11
149	Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase C η inhibition and renin-angiotensin system blockade: a pilot study. 2012 , 90, 113-21	8
148	Therapeutic Modalities in Diabetic Nephropathy: Future Approaches. 2012 , 2, 5-18	10
147	Type-2 Diabetes and Associated Comorbidities as an Inflammatory Syndrome. 2012 , 159-175	1

146	Antioxidant Therapy for Diabetic Kidney Disease. 2012,	1
145	The connection between GRKs and various signaling pathways involved in diabetic nephropathy. 2012, 39, 7717-26	3
144	What are new avenues for renal protection, in addition to RAAS inhibition?. 2012, 14, 100-10	8
143	Update on potential drugs for the treatment of diabetic kidney disease. 2012, 34, 1237-46	17
142	A brief history of insulin resistance: from the first insulin radioimmunoassay to selectively targeting protein kinase C pathways. 2012, 61, 445-9	6
141	New options and perspectives for proteinuria management after kidney transplantation. 2012, 26, 44-52	9
140	Vascular complications of diabetes: mechanisms of injury and protective factors. 2013, 17, 20-33	417
139	Local cAMP signaling in disease at a glance. 2013, 126, 4537-43	53
138	Diabetic nephropathy: diagnosis and treatment. 2013, 9, 713-23	164
137	Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. 2013, 58, 259-71	130
136	From peptides to peptidomimetics: rational design of potential PKC- β inhibitors. 2013, 22, 625-634	
135	The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. 2013, 83, 887-900	82
134	Pathophysiology and Pathogenesis of Diabetic Nephropathy. 2013, 2605-2632	3
133	Emerging drugs for managing kidney disease in patients with diabetes. 2013, 18, 55-70	7
132	Potential new treatments for diabetic kidney disease. 2013, 97, 115-34	10
131	[Diabetes and kidneys]. 2013, 138, 949-55	2
130	Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease. 2013, 305, F1542-3	2
129	The insulin receptor and the kidney. 2013, 22, 100-6	26

128	Dual inhibition of classical protein kinase C- α and protein kinase C- δ isoforms protects against experimental murine diabetic nephropathy. 2013 , 62, 1167-74		51
127	Current Update in the Management of Diabetic Nephropathy. 2013 , 9, 62-77		38
126	Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. <i>BioMed Research International</i> , 2014 , 2014, 801269	3	111
125	Diabetic nephropathy - complications and treatment. 2014 , 7, 361-81		286
124	Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy. 2014 , 8, 1867-1873		20
123	[Importance of diabetic nephropathy in childhood. Clinical findings and basic research in recent decades]. 2014 , 155, 141-50		1
122	Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. 2014 , 5, 1-20		3
121	Therapeutic approaches to diabetic nephropathy--beyond the RAS. 2014 , 10, 325-46		131
120	New insights into molecular mechanisms of diabetic kidney disease. 2014 , 63, S63-83		117
119	Diabetic Cardiomyopathy. 2014 ,		2
118	Roles of PKC Isoforms in Development of Diabetes-Induced Cardiovascular Complications. 2014 , 269-284		
117	Novel effective drugs for diabetic kidney disease? or not?. 2014 , 19, 571-601		13
116	Have we reached the limits for the treatment of diabetic nephropathy?. 2014 , 23, 511-22		19
115	[Diabetic nephropathy: emerging treatments]. 2014 , 10, 210-5		2
114	Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats. 2014 , 220, 129-41		9
113	Comprehensive approach to diabetic nephropathy. 2014 , 33, 121-31		61
112	Novel therapies for diabetic kidney disease. 2014 , 21, 121-33		26
111	Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory?. 2014 , 88, 139-49		29

110	Diabetic kidney disease: from physiology to therapeutics. 2014 , 592, 3997-4012	86
109	The Protein Kinase C Inhibitor: Ruboxistaurin. 2016 , 55, 295-301	17
108	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. 2015 , 4, 1325-47	44
107	Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. 2015 , 2015, 697010	89
106	Present and future in the treatment of diabetic kidney disease. 2015 , 2015, 801348	26
105	Updates in the management of diabetic nephropathy. 2015 , 4, 9-14	
104	Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. 2015 , 129, 29-33	43
103	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. 2015 , 30 Suppl 4, iv1-5	8
102	Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial. 2015 , 65, 634-6	17
101	PKC- β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. 2015 , 106, 303-13	45
100	Management of diabetic nephropathy: Recent progress and future perspective. 2015 , 9, 343-58	95
99	Therapies on the Horizon for Diabetic Kidney Disease. 2015 , 15, 111	20
98	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. 2015 , 28, 167-74	10
97	Obstructive Sleep Apnea and Diabetic Microvascular Complications. 2015 , 213-224	
96	Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. 2015 , 20, 332-46	64
95	Pathophysiology of Diabetic Nephropathy. 2015 , 151-162	1
94	Slowing Progression of Chronic Kidney Disease. 2015 , 598-612	1
93	Complications of Diabetes Mellitus. 2016 , 1484-1581	11

92	Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial. <i>PLoS ONE</i> , 2016 , 11, e0152357	3-7	5
91	Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF- β /Smad and GRAP pathways. 2016 , 68, 219-32		20
90	Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. 2016 , 791, 8-24		153
89	Prostaglandin I2 Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?. 2016 , 65, 1149-51		
88	Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways. 2016 , 310, H153-73		51
87	Diabetic Nephropathy. 2016 , 934-957.e12		1
86	Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?. 2016 , 31, 393-405		18
85	Novel avenues for treating diabetic nephropathy: new investigational drugs. 2017 , 26, 445-462		17
84	Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. 2017 , 312, F716-F731		105
83	Diabetic Kidney Disease: Challenges, Progress, and Possibilities. 2017 , 12, 2032-2045		739
82	A perspective on chronic kidney disease progression. 2017 , 312, F375-F384		57
81	Wnt signaling and podocyte dysfunction in diabetic nephropathy. 2017 , 65, 1093-1101		47
80	Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders. 2017 , 78, 203-301		50
79	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. 2017 , 102, 4343-4410		185
78	Targeting Complications of Diabetes with Antioxidants. 2017 , 397-445		1
77	Recent Advances in Management of Diabetic Nephropathy. 2017 , 02,		3
76	Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice. 2017 , 11, 1065-1079		26
75	High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling. 2017 , 58, 794-802		7

74	Phylogeny and distribution of protein kinase C variants in the zebrafish. 2018 , 526, 1097-1109		6
73	Update of pathophysiology and management of diabetic kidney disease. 2018 , 117, 662-675		158
72	Specific PKC β inhibitor: one stone two birds in the treatment of diabetic foot ulcers. 2018 , 38,		8
71	Secretogranin III: a diabetic retinopathy-selective angiogenic factor. <i>Cellular and Molecular Life Sciences</i> , 2018 , 75, 635-647	10.3	14
70	Antidiabetic Activity of Curcumin. 2018 , 385-401		4
69	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2018 , 1-42	0.1	
68	An effect of combination of resveratrol with vitamin D3 on modulation of proinflammatory cytokines in diabetic nephropathy induces rat. <i>Oriental Pharmacy and Experimental Medicine</i> , 2018 , 18, 127-138	2	4
67	Antioxidant, Anti-Inflammatory, and Metabolic Properties of Tocopherols and Tocotrienols: Clinical Implications for Vitamin E Supplementation in Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	22
66	Effect of safflower yellow on early type II diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2019 , 32, 653-665	1.6	5
65	Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study. <i>Chinese Journal of Integrative Medicine</i> , 2019 , 25, 168-174	2.9	2
64	Diabetic Kidney Disease. 2019 , 42-61.e5		
63	Managing chronic kidney disease in diabetes patients with the latest chemical therapies. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 53-60	3.8	1
62	Pathophysiology of Diabetic Nephropathy. 2020 , 279-296		4
61	The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. <i>Endocrine Reviews</i> , 2020 , 41,	27.2	29
60	Identification of hub genes in diabetic kidney disease via multiple-microarray analysis. <i>Annals of Translational Medicine</i> , 2020 , 8, 997	3.2	7
59	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020 , 33, 931-948	4.8	4
58	Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated With Downregulation of AQP2 and Increased Urinary Uric Acid Excretion. <i>Frontiers in Pharmacology</i> , 2020 , 11, 49	5.6	13
57	Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22 Suppl 1, 16-31	6.7	33

56	The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies. <i>Medicinal Research Reviews</i> , 2021 , 41, 202-222	14.4	10
55	Diabetic Kidney Disease Represents a Locus of Opportunity. <i>Frontiers in Physiology</i> , 2021 , 12, 650503	4.6	
54	Insulin actions on vascular tissues: Physiological effects and pathophysiological contributions to vascular complications of diabetes. <i>Molecular Metabolism</i> , 2021 , 52, 101236	8.8	7
53	Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options. <i>PeerJ</i> , 2021 , 9, e11070	3.1	1
52	Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. <i>BioMed Research International</i> , 2021 , 2021, 1497449	3	39
51	Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure. 2021 , 2,		0
50	Regulation of Solute Carriers OCT2 and OAT1/3 in the Kidney: A Phylogenetic, Ontogenetic and Cell Dynamic Perspective. <i>Physiological Reviews</i> , 2021 ,	47.9	2
49	Pathogenesis and Pathophysiology of Diabetic Nephropathy. 2009 , 214-223		4
48	Complications of Diabetes Mellitus. 2011 , 1462-1551		7
47	Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107613	3.2	29
46	Complexity of diabetic nephropathy pathogenesis and design of investigations. <i>Journal of Renal Injury Prevention</i> , 2013 , 2, 59-62	1	32
45	Exercise protects against diet-induced insulin resistance through downregulation of protein kinase C in mice. <i>PLoS ONE</i> , 2013 , 8, e81364	3.7	23
44	Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?. <i>Current Pharmaceutical Design</i> , 2019 , 25, 2171-2177	3.3	8
43	Knockout mouse models of insulin signaling: Relevance past and future. <i>World Journal of Diabetes</i> , 2014 , 5, 146-59	4.7	22
42	Evolving pandemic diabetic nephropathy. <i>Rambam Maimonides Medical Journal</i> , 2010 , 1, e0005	1.8	11
41	Species differences in regulation of renal proximal tubule transport by certain molecules. <i>World Journal of Nephrology</i> , 2015 , 4, 307-12	3.6	4
40	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. <i>Yearbook of Medicine</i> , 2006 , 2006, 472-474		
39	Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications. 2007 , 219-228		

38	Microvascular Complications. <i>Endocrine Practice</i> , 2007 , 13, 50-55	3.2
37	Clinical Trials in Protein Kinase C-Inhibition in Diabetic Retinopathy. 2008 , 423-434	
36	Therapy for Diabetic Nephropathy. 2008 , 323-333	
35	Tubulointerstitialnyy fibroz pri diabeticheskoy nefropatii: mekhanizmy razvitiya i podkhody k lecheniyu. <i>Diabetes Mellitus</i> , 2008 , 11, 11-15	1.6 2
34	The Future of Diabetes Therapy. 2010 , 787-800	
33	Prevention of Microvascular Complications of Diabetes [General Overview]. 2010 , 749-753	
32	Diabetic Nephropathy. 2011 , 1411-1454	6
31	Therapeutic Drug Development for Kidney Diseases.	
30	Diabetic Nephropathy. 2015 , 1-18	
29	Prevention of Microvascular Complications of Diabetes: General Overview. 2016 , 1-9	
28	Diabetic Nephropathy. 2017 , 1-18	
27	Diabetic Nephropathy. 2017 , 425-442	1
26	Prevention of Microvascular Complications of Diabetes: General Overview. 2017 , 947-955	
25	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2018 , 161-201	0.1
24	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2019 , 1-41	0.1
23	Wogonin and alleviation of hyperglycemia via inhibition of DAG mediated PKC expression. A brief insight. <i>Protein and Peptide Letters</i> , 2021 ,	1.9 0
22	Pharmacologic inhibition of Protein Kinase C and Protein Kinase C halts renal function decline indirectly, by blunting hyperphagia, and directly reduces adiposity in the ZSF1 rat model of type 2 diabetes.	
21	Pathogenesis of Microvascular Complications. <i>Endocrinology</i> , 2020 , 161-201	0.1

20	Diabetic kidney disease: seven questions. <i>Journal of the Korean Medical Association</i> , 2020 , 63, 6	0.5	
19	Pathophysiology. 2020 , 5-22		
18	Screening and Treatment of Early Diabetic Renal Disease in Type 1 and Type 2 Diabetes. 2006 , 403-417		
17	Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. <i>Vascular Health and Risk Management</i> , 2007 , 3, 823-32	4.4	32
16	Factors associated with the psychological status during the Coronavirus pandemic, baseline data from an Iranian Province. <i>Caspian Journal of Internal Medicine</i> , 2020 , 11, 484-494	1	0
15	Diabetic kidney disease-predisposing proinflammatory and profibrotic genes identified by weighted gene co-expression network analysis (WGCNA).. <i>Journal of Cellular Biochemistry</i> , 2021 ,	4.7	3
14	Image_1.jpeg. 2020 ,		
13	Image_2.tif. 2020 ,		
12	Prospective dietary radical scavengers: Boon in Pharmacokinetics, overcome insulin obstruction via signaling cascade for absorption during impediments in metabolic disorder like Diabetic Mellitus. <i>Journal of Diabetes and Metabolic Disorders</i> , 1	2.5	0
11	Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7	3
10	Oncoprotein DJ-1 interacts with mTOR complexes to effect transcription factor Hif1 α dependent expression of collagen I (α) during renal fibrosis. <i>Journal of Biological Chemistry</i> , 2022 , 102246	5.4	0
9	The Role of PKC-MAPK Signalling Pathways in the Development of Hyperglycemia-Induced Cardiovascular Complications. 2022 , 23, 8582		1
8	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. 2022 , 23, 10882		0
7	The Role of Diacylglycerol Kinase in the Amelioration of Diabetic Nephropathy. 2022 , 27, 6784		0
6	Emerging drugs for the treatment of diabetic nephropathy. 2022 , 27, 417-430		0
5	Diabetic Kidney Care Redefined with a New Way into Remission. 2022 ,		0
4	<i>Punica granatum</i> L. Polyphenolic Extract as an Antioxidant to Prevent Kidney Injury in Metabolic Syndrome Rats. 2023 , 2023, 1-14		0
3	Effects of antioxidants on diabetic kidney diseases: mechanistic interpretations and clinical assessment. 2023 , 18,		0

2 Mechanisms of Diabetic Nephropathy in Humans and Experimental Animals. **2023**, 129-151 ○

1 Quantitative proteomics combined with network pharmacology analysis unveils the biological basis of Schisandrin B in treating diabetic nephropathy. ○